卡米尔1-AA可以选择性地抑制巨型皮诺细胞形成,同时节省自
Rebecca M Lim1, Alexa Lu2, Brennan M Chuang1
1Department of Developmental and Cell Biology, Charlie Dunlop School of Biological Sciences, University of California, Irvine, CA 92617.
Molecular biology of the cell
|November 27, 2024
概括
癌细胞使用巨型皮诺细胞形成来生长和抵抗药物. 一种新的CARMIL1-AA突变选择性地抑制了巨细胞细胞形成,而不会影响细胞增殖或自.
科学领域:
- 细胞生物学 细胞生物学
- 癌症研究 癌症研究
- 分子生物学分子生物学
背景情况:
- 巨细胞酶促进瘤生长和耐药性,使癌细胞能够内部化细胞外巨分子.
- 选择性抑制巨细胞细胞形成对于了解其在癌症中的确切作用至关重要.
- 广泛使用的抑制剂EIPA会影响多个Na+/H+交换器 (NHE),导致pH和增殖的非目标效应.
研究的目的:
- 开发一种选择性抑制宏皮诺细胞形成的药物.
- 评估巨细胞在癌症进展中的作用,独立于其抑制剂的副作用.
- 研究CARMIL1-AA作为选择性巨细胞酶抑制剂的疗效.
主要方法:
- 通过CRISPR-Cas9基因编辑来破坏CARMIL1.1.
- 一个CARMIL1-AA突变体的表达以抑制巨细胞.
- 评估巨型皮诺细胞形成,增殖,RAC激活和自.
- 使用抑制剂EIPA和NHE1敲击进行比较.
主要成果:
- EIPA 抑制了比宏皮诺细胞结合更强的增殖,并触发了ATG8 结合 (CASM).
- 损失NHE1并没有阻断巨细胞形成,并且具有异于目标的pH效应.
- 卡米尔1-AA表达选择性地抑制了巨细胞形成,而不会影响增殖或自.
- 卡米尔1-AA显示出与EIPA相似的抑制作用,但没有EIPA的副作用.
结论:
- 卡米尔1-AA是一种选择性的巨细胞酶抑制剂,为研究癌症提供了比EIPA更好的工具.
- 通过CARMIL1-AA选择性抑制巨细胞细胞形成并不会阻碍细胞增殖或自.
- 用 CARMIL1-AA 等选择性抑制剂向巨细胞细胞形成是癌症研究的一个有希望的策略.
相关概念视频
Autophagy
4.2K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.2K
Pinocytosis
3.2K
Cells use energy-requiring bulk transport mechanisms to transfer large particles or large numbers of small particles into or out of the cell. The cells envelop the particles in spherical membranes called vesicles or vacuoles. Vesicles that transport material into the cell are built from the cell membrane. These vesicles encapsulate external molecules and transport them into the cell in a process called endocytosis.
Pinocytosis ("cellular drinking") is one of three main types of...
Pinocytosis ("cellular drinking") is one of three main types of...
3.2K
Delivery Pathways to the Lysosome
6.2K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
6.2K
Autophagic Cell Death
3.4K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.4K
Pinching-off of Coated Vesicles
3.1K
Vesicle budding is orchestrated by distinct cytosolic proteins such as adaptor proteins, coat proteins, and GTPases. To initiate vesicle budding, membrane-bending proteins containing crescent-shaped BAR domains bind to the lipid heads in the bilayer and distort the membrane to form a protein-coated vesicle bud. Adaptors proteins such as AP2 for clathrin-coated vesicles can nucleate on the deformed membrane. Finally, coat proteins such as clathrin or COPI and COPII assemble into a coat forming...
3.1K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


